From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?

From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?

CLICK HERE FOR CME CREDIT

From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?

 

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY